Spero Therapeutics, Inc. (SPRO): Shareholders' Equity
$59.02M
As of 2025-12-31
$44.20M
As of 2026-06-30
-8.1%
3-year compound annual growth
-14.9%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.02M | +28.0% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $46.12M | -56.9% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $106.89M | +40.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $75.93M | -14.0% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $88.29M | -33.1% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $132.04M | +77.1% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $74.57M | -35.4% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $115.50M | +36.5% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $84.60M | n/m | 2019-03-14, Balance as of period end |
| 2016-12-31 | -$45.44M | n/a | 2018-04-02, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $64.72M | -49.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $36.98M | +13.5% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $722.17M | +7.5% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $305.72M | -34.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $346.18M | +73.5% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $206.75M | +519.8% |
Compare SPRO, KURA, ENTA, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗